A potential therapy targeting difficult-to-treat immune system disorders such as rheumatoid arthritis will progress to clinical trials next year after securing $20 million in Series A funding.
1 November 2019A potential therapy targeting difficult-to-treat immune system disorders such as rheumatoid arthritis will progress to clinical trials next year after securing $20 million in Series A funding.
1 November 2019